Tsubota Laboratory, Inc.

Keio University

Toshiba Materials Co., Ltd.

Agc Inc.

Riken Corporation

Konami Digital Entertainment Co., Ltd.

Nagoya Institute of Technology

Rohto Pharmaceutical Co., Ltd.

Jins Holdings Inc.

Oryza Oil & Fat Chemical Co., Ltd.

Restore Vision Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Kazuo Tsubota

Toshihide Kurihara

Hidemasa Torii

Shin Hatou

Shigeto Shimmura

Masahiko Yamakawa

Hideki Kandori

Yusaku Katada

Kazuno Negishi

Shigeru Nakamura

Satoru Yoshida

Manabu Nishizawa

Akio Koike

Junji Tanaka

Tetsuya Nakashima

Hiroshi Shimoda

Satoshi Wada

Hideyuki Okano

Kensuke Nagai

Hiroyuki Hijiya

Shinichi Ikeda

Yutaka Kuroiwa

Masamichi Tanida

Akihiro Higuchi

Hiromichi Murai

Shogo Azuma

Masataka Ito

Akiyoshi Kishino

Shunsuke Shioya

Kensaku Yoshida

Reiko Arita

Atsushi Shinjo

Xiaoyan Jiang

Hiromitsu Kunimi

Emi Inagaki

Toshihiro Imada

Toshihiro Kusano

Takashi Kadekaru

Kiyoshi Fukuhara

Masahiro Omoto

Miho Maeda

A model that closely resembles human excessive myopia can be prepared by mounting a minus lens () and a protector () to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Mouse myopia-induced model and endoplasmic reticulum stress suppressant for preventing and suppressing myopia

Using the medium of the present invention for inducing a cornea endothelial substitute cell from an iPS cell, the medium containing an insulin-like growth factor and a STAT3 activator, and not containing a basic fibroblast growth factor or a ROCK inhibitor, and the method of the present invention for inducing corneal endothelial substitute cells from iPS cells by using the medium, it becomes possible to efficiently produce corneal endothelial substitute cells, particularly to efficiently produce corneal endothelial substitute cells from iPS cells. Furthermore, it becomes possible to stably produce large amounts of corneal endothelial substitute cells by inducing differentiation of iPS cells into corneal endothelial substitute cells more efficiently.

Medium comprising serum replacement, IGF1, STAT3 activator and adrenal gland hormone without BFGF or rock inhibitor for producing corneal endothelial substitute cells from iPS cells and a method thereof

A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Light source for myopia prevention article and method of using light source for myopia prevention article

The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.

Agent for restoring visual function or agent for preventing deterioration in visual function

The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Composition and functional food for preventing myopia

Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Nucleic acid construct that encodes chimeric rhodopsin

The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.

Rapid tumorigenicity screening system

This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Method of improving lacrimal secretion for dry eye treatment using maqui berry extract

A wavelength-selective transmissive glass has a light transmittance Tat a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance Tat a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ais a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tis a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm:=(&#x3a3;)/(&#x3a3;)=(&#x3a3;)/(&#x3a3;).

Glass

An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.

Optical element

The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.

Myopia treatment device

To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system () including a first light-emitting element () that emits light used for image display, a second light-emitting element () that irradiates light () within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit () that controls irradiation of the light () from the second light-emitting element ().At this time, the second light-emitting element () may be a single light-emitting element integrated with the first light-emitting element () or a light-emitting element provided separately from the first light-emitting element (). When separately provided from the first light-emitting element (), the second light-emitting element () is preferably provided to a peripheral frame () of a display screen (), in the display screen (), or as an accessory ().

Display system, electronic device, and lighting system

A lottery device includes: a drawing body having medium entrance units which are provided along a circumferential direction thereof, and into each of which a game medium can enter; a driving mechanism driving the drawing body in the circumferential direction; a dividing device dividing a periphery of a path of the medium entrance units, in which path the medium entrance units travel, into lottery segments in the circumferential direction; a medium introduction mechanism introducing the game medium individually into each lottery segment; an entrance unit detection device detecting a medium entrance unit into which the game medium has entered; a displacement amount detection device detecting an amount of displacement in the circumferential direction; and a lottery segment distinguishing device distinguishing from which of the lottery segments the game medium has entered into the medium entrance unit based on a result of detection by the displacement amount detection device.

Lottery device and game machine using same

The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.

Method for producing therapeutic corneal endothelial substitute cell sphere

Growing community of inventors

Tokyo, Japan

Kazuo Tsubota